Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-University, Munich, Germany.
Epilepsia. 2010 Sep;51(9):1780-90. doi: 10.1111/j.1528-1167.2010.02671.x. Epub 2010 Jul 14.
Based on experimental findings, overexpression of P-glycoprotein at the blood-brain barrier has been suggested to be a contributor to pharmacoresistance of the epileptic brain. We test a technique for evaluation of interindividual differences of elevated transporter function, through microPET analysis of the impact of the P-glycoprotein modulator tariquidar. The preclinical study is intended for eventual translation to clinical research of patients with pharmacoresistant seizure disorders.
We made a microPET evaluation of the effects of tariquidar on the brain kinetics of the P-glycoprotein substrate [(18) F]MPPF in a rat model with spontaneous recurrent seizures, in which it has previously been demonstrated that phenobarbital nonresponders exhibit higher P-glycoprotein expression than do phenobarbital responders.
Mean baseline parametric maps of the [(18) F]MPPF unidirectional blood-brain clearance (K(1) ; ml/g per min) and the efflux rate constant (k(2) ; per min) did not differ between the nonresponder and responder group. Tariquidar pretreatment increased the magnitude of [(18) F]MPPF K(1) in hippocampus by a mean of 142% in the nonresponders, which significantly exceeded the 92% increase observed in the responder group. The same treatment decreased the mean magnitude of [(18) F]MPPF k(2) in hippocampus by 27% in nonresponders, without comparable effects in the responder group.
These results constitute a proof-of-concept for a novel imaging approach to evaluate blood-brain barrier P-glycoprotein function in animals. By extension, [(18) F]MPPF positron emission tomography (PET) with tariquidar pretreatment may be amenable for clinical applications exploring further the relevance of P-glycoprotein overexpression, and for enabling the rational design of pharmacotherapy according to individual differences in P-glycoprotein expression.
基于实验发现,血脑屏障上 P-糖蛋白的过度表达被认为是癫痫大脑药物耐药的一个原因。我们测试了一种评估个体间转运体功能升高差异的技术,通过 microPET 分析 P-糖蛋白调节剂塔里奎达对脑内的影响。该临床前研究旨在最终转化为对药物难治性癫痫患者的临床研究。
我们在具有自发性复发性癫痫的大鼠模型中进行了 microPET 评估,研究塔里奎达对 P-糖蛋白底物 [(18)F]MPPF 脑内动力学的影响,此前已证明苯巴比妥无反应者的 P-糖蛋白表达高于苯巴比妥反应者。
[(18)F]MPPF 单向血脑清除率(K1;ml/g/分钟)和外排率常数(k2;每分钟)的基线参数图在无反应者和反应者组之间没有差异。塔里奎达预处理使无反应者的 [(18)F]MPPF K1 增加了 142%,这明显高于反应者组的 92%增加。同样的治疗使无反应者的 [(18)F]MPPF k2 平均降低了 27%,而在反应者组没有类似的影响。
这些结果构成了一种新的成像方法的概念验证,用于评估动物血脑屏障 P-糖蛋白功能。通过扩展,用塔里奎达预处理的 [(18)F]MPPF 正电子发射断层扫描(PET)可能适用于临床应用,进一步探索 P-糖蛋白过度表达的相关性,并根据 P-糖蛋白表达的个体差异为合理设计药物治疗提供依据。